GlassScriptPhysician profile
Nema David Ayadpoor
NPI 1205228350
$6,577.29
in general payments reported to CMS, 2019-2025
24 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,267 · 2022: $1,199 · 2023: $1,619 · 2024: $1,297 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Travel and Lodging: $1,161 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.46 |
| Travel and Lodging | $1,161.40 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,368.59 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,023.78 | 2021-2025 | Lifevest |
| Abbott Laboratories | $734.52 | 2022-2025 | Aveir, Jot Dx, Gallant |
| E.R. Squibb & Sons, L.L.C. | $727.35 | 2021-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $556.91 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $360.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $356.62 | 2021-2024 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $335.19 | 2021 | |
| Amgen INC. | $261.98 | 2022-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.17 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $133.73 | 2022 | |
| Philips North America LLC | $88.96 | 2024 | (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $84.92 | 2021-2025 | |
| Pfizer INC. | $67.18 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $58.24 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $54.03 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $44.80 | 2021 | |
| Convatec INC. | $21.92 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.63 | 2024 | Onpattro |
| Amarin Pharma, INC. | $18.46 | 2022 | |
| Recor Medical INC | $15.56 | 2024 | Paradise Renal Denervation System |
| Bardy Diagnostics, INC. | $15.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.45 | 2022 | |
| Impulse Dynamics (USA) INC. | $12.78 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nema Ayadpoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.